PADI2 and cancer: Therefore, a difference in prominence of the three main PAD isozymes (PAD2, 3, and 4) related to cancers is a topic of current interest, in relation to isozyme-specific targeting for specific cancer types, including heterogenous cancers as well as cancer subtypes [15,17].